ST Pharm Co Ltd
KOSDAQ:237690
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
67 300
139 700
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| KR |
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
2.4T KRW |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.3T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
241.5B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
169.6B USD |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
38.1B CHF |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
40.7B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
280.3B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
39.3B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
83.2T KRW |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
29.4B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
23.8B USD |
Loading...
|
Market Distribution
| Min | -168 471.3% |
| 30th Percentile | -2.9% |
| Median | 1.9% |
| 70th Percentile | 5.8% |
| Max | 21 012.5% |
Other Profitability Ratios
ST Pharm Co Ltd
Glance View
Nestled in the bustling metropolis of Seoul, South Korea, ST Pharm Co Ltd. operates as a dynamic player within the global pharmaceutical industry. Established initially to meet the burgeoning demands of the local pharmaceutical market, the company has slowly carved out a niche for itself in the global arena. With a deft focus on the development and manufacture of active pharmaceutical ingredients (APIs), ST Pharm now sets its sights on becoming a central figure in the synthesis of high-value APIs used in therapies including antivirals and oncology treatments. This focus isn't merely driven by opportunity; it's underpinned by a dedicated commitment to cutting-edge research and development. The company has invested heavily in state-of-the-art facilities and nurtures a team of seasoned scientists who remain at the forefront of innovation. ST Pharm makes its revenue by mastering the art of efficient and reliable API production. By optimizing their production processes, they can offer a competitive edge—delivering high-quality products at scale. The company isn't solely interested in the immediate gains of API manufacture; it also sees potential in providing customized solutions to its diverse clientele, which spans multinational pharmaceutical giants to nimble biotech startups. Partnerships and collaborations have become crucial strategies for ST Pharm, facilitating an exchange of innovation and expertise that keeps them relevant and forward-thinking. In this regard, their business model elegantly balances between standardized API production and bespoke chemical solutions, ensuring a steady revenue stream while opening doors to future advancements in pharmaceutical science.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for ST Pharm Co Ltd is 11.6%, which is above its 3-year median of 8.9%.
Over the last 3 years, ST Pharm Co Ltd’s Net Margin has increased from 5.5% to 11.6%. During this period, it reached a low of 4.4% on Sep 30, 2023 and a high of 12.7% on Dec 31, 2024.